Product Information
ALOGLIPTIN-PIOGLIT 25-30 MG TB is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $5.7169 per EA under NDC 45802040265. Its NADAC has been published 182 times since Nov 23, 2016.
FDA first approved this application on Jan 25, 2013.
Strength
25; 30 mg/1; mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802040265
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
1/22/2025
Active Ingredients
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA022426FDA Approved
1/25/2013
On Market Since
4/8/2016
Pharmacological Classes
Price Statistics
The NADAC for ALOGLIPTIN-PIOGLIT 25-30 MG TB has been published 182 times since Nov 23, 2016, and over the history we have for it it has declined 8.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.7169 per EA |
|---|---|
| All-time high | $6.4807 (Sep 13, 2017) |
| All-time low | $4.6594 (May 22, 2024) |
| 52-week high | $5.7169 |
| 52-week low | $5.7169 |
| Median price | $5.7801 |
| Average price | $5.8124 |
| Largest weekly change | -19.4% (May 22, 2024) |
| Weeks tracked | 182 |
| Tracking since | Nov 23, 2016 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
0.0%
3Y
-1.1%
5Y
-1.1%
All
-8.8%
Last surveyed Jan 14, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Alogliptin Benzoate and Pioglitazone hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ALOGLIPTIN-PIOGLIT 25-30 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for ALOGLIPTIN-PIOGLIT 25-30 MG TB, manufactured by Padagis Israel Pharmaceuticals Ltd, is $5.7169 per EA (NDC 45802040265), effective Jan 14, 2026.
How has the price of ALOGLIPTIN-PIOGLIT 25-30 MG TB changed over time?
Over the history we have for it, the NADAC for ALOGLIPTIN-PIOGLIT 25-30 MG TB has declined 8.8%. It has been tracked across 182 weekly CMS publications since Nov 23, 2016.
What are the highest and lowest recorded NADAC prices for ALOGLIPTIN-PIOGLIT 25-30 MG TB?
Since Nov 23, 2016, the NADAC for ALOGLIPTIN-PIOGLIT 25-30 MG TB has ranged from a low of $4.6594 (May 22, 2024) to a high of $6.4807 (Sep 13, 2017), with a median of $5.7801 per EA.
Are there cheaper alternatives to ALOGLIPTIN-PIOGLIT 25-30 MG TB?
No other NADAC-published product currently shares the active ingredient and strength of ALOGLIPTIN-PIOGLIT 25-30 MG TB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ALOGLIPTIN-PIOGLIT 25-30 MG TB?
ALOGLIPTIN-PIOGLIT 25-30 MG TB (NDC 45802040265) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.